INVESTIGADORES
ZANETTI Flavia Adriana
congresos y reuniones científicas
Título:
RECOMBINANT MVA EXPRESSING SECRETED GLYCOPROTEIN D AS A CANDIDATE VACCINE AGAINST BoHV-1
Autor/es:
FERRER, M. F.; DEL MÉDICO ZAJAC M. P.; ZANETTI F. A.; VALERA A. R.; ZABAL O.; CALAMANTE G.
Lugar:
Gramado
Reunión:
Encuentro; XXI Encontro Nacional de Virologia.V Encontro de Virologia do Mercosul; 2010
Resumen:
Poxviruses have been efficiently used as effective and safe vaccines to prevent infectious diseases. Particularly, modified vaccinia virus Ankara (MVA) was evaluated in phase I/II HIV-1, tuberculosis, malaria and relevant tumour antigens trials. There were no serious complications after using MVA as a non-replicative vaccine vector confirming its safety profile. MVA was derived from chorioalantoid vaccinia Ankara strain after 570 passages in chicken-embryo fibroblasts, losing its ability to productively replicate in most mammalian cells. Due to MVA ability of inducing specific humoral and cellular immune responses without replication, this virus has became a good candidate to develop new veterinary vaccines. Bovine herpesvirus-1 (BoHV-1) infection is distributed worldwide and there are no efficacious vaccines to prevent it. In this context the development of new tools to fight against this pathogen becomes extremely important. In this work a MVA vector expressing the secreted version of glycoprotein D, MVA-gDs, was obtained and evaluated as a candidate vaccine. Firstly, the correct expression, antigenicity and N-glycosilation of glycoprotein D were confirmed by molecular techniques. Then, MVA-gDs was used as parenteral immunogen in BALB/c mice where a specific anti-gD humoral immune response was induced and maintained for seven months. Besides, two doses of MVA-gDs supplemented with cholera toxin delivered by intranasal immunization induced anti-gD IgA humoral immune response in nasal and bronchiopulmonar washes as well as anti-gD IgG antibodies in serum samples. In order to evaluate the protection conferred by MVA-gDs immunization, a rabbit BoHV-1 challenge assay was performed. A shorter viral excretion period and a reduction on the number of animals shedding BoHV-1 was observed in those animals immunized with recombinant MVA-gDs. In conclusion our data encourage MVA-gDs evaluation as a candidate vaccine for BoHV.